Add to my selection

BRIUMVI (ublituximab)

Medicine - Posted on Jan 22 2025

Active substance (DCI)

ublituximab

history (1)

1/15/25

BRIUMVI (ublituximab) - Multiple sclerosis (MS)

Summary of opinion Favourable opinion for reimbursement in the treatment of adult patients with relapsing forms of multiple ...

CAV :
54321

icône flèche

Technical information

ATC code

L04AG14

Manufacturer

NEURAXPHARM

Presentation

BRIUMVI 150 mg, solution à diluer pour perfusion
1 flacon en verre de 6 mL (CIP : 34009 550 986 7 6)
3 flacons en verre de 6 mL (CIP : 34009 551 012 1 5)

All our publications

Autoimmune diseases

Central nervous system diseases

Demyelinating diseases

Drug therapy

My account

You do not have a saved search

No element in selection

BRIUMVI (ublituximab)

BRIUMVI (ublituximab) - Multiple sclerosis (MS)

Follow us :